Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration
Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration
复制标题
DOI：
10.3928/1542-8877-20050701-14
复制
发表时间：
2005-07-01
影响因子：
--
通讯作者：
Puliafito, CA
中科院分区：
文献类型：
--
作者：
Rosenfeld, PJ;Moshfeghi, AA;Puliafito, CA
为了确定玻璃体内注射贝伐珠单抗是否可以改善对哌加他尼治疗反应较差的新生血管性年龄相关性黄斑变性患者的光学相干断层扫描和视力结局，给予玻璃体内注射贝伐珠单抗（1.0 mg）。在1周内，光学相干断层扫描显示视网膜下液体的解决，导致正常的黄斑轮廓。改善的黄斑外观维持至少4周，视力保持稳定。未观察到炎症。玻璃体内注射贝伐单抗可能为继发于黄斑新生血管的老年性黄斑变性患者提供一种有效、安全且廉价的选择。
To determine whether intravitreal bevacizumab could improve optical coherence tomography and visual acuity outcomes in a patient with neovascular age-related macular degeneration who was responding poorly to pegaptanib therapy, an intravitreal injection of bevacizumab (1.0 mg) was given. Within 1 week, optical coherence tomography revealed resolution of the subretinal fluid, resulting in a normal-appearing macular contour. The improved macular appearance was maintained for at least 4 weeks, and visual acuity remained stable. No inflammation was observed. An intravitreal injection of bevacizumab may provide an effective, safe, and inexpensive option for patients with age-related macular degeneration who are losing vision secondary to macular neovascularization.